| Cat. No. |
Product Name |
Information |
| PC-24548 |
BCX9930
Factor D inhibitor
|
BCX9930 (Pelecopan) is a potent, selective oral inhibitor of complement Factor D with IC50 of 14.3 nM (purified human factor D), inhibits the activation of the complement alternative pathway (AP). |
| PC-21586 |
C1s inhibitor A1
C1s inhibitor
|
C1s inhibitor A1 is a selective, competitive inhibitor of complement component C1s with binding Kd of 9.8 uM, competitively inhibits its activity with Ki of 5.8 uM. |
| PC-20806 |
NSC33353
C5a receptor inhibitor
|
NSC33353 (NSC 33353) is a small molecule inhibitor with potent anti-tumor activity against TNBC cells, enhances TNBC sensitivity to doxorubicin, also is an inhibitor of C5a receptor binding. |
| PC-20173 |
Sepimostat
Multi-protease inhibitor
|
Sepimostat (FUT-187) is a potent multi-protease inhibitor with IC50 of 0.097 uM for trypsin, 0.029 uM for pancreatic kallikrein, 0.61 uM for plasma kallikrein, 0.57uM for plasmin, 2.5 uM for thrombin, 20.4 uM for factor Xa and 6.4 uM for C1r. |
| PC-38846 |
W54011
C5aR inhibitor
|
W-54011 (W54011) is a potent, selective, orally active and non-peptide C5a receptor antagonist, inhibits the binding of 125I-labeled C5a to human neutrophils with Ki of 2.2 nM. |
| PC-38845 |
PMX205
C5aR inhibitor
|
PMX205 is a potent, selective C5a receptor peptide antagonist with IC50 of 30 nM. |
| PC-38358 |
Vemircopan
Factor D inhibitor
|
Vemircopan (ALXN2050, ACH 5228) is a second generation, orally active complement factor D inhibitor, has the potential to decrease disease symptoms and increase strength in generalized myasthenia gravis (gMG). |
| PC-38352 |
JYN42346
Factor D inhibitor
|
JYN42346 (Complement factor D-IN-2) is an inhibitor of complement factor D, inhibits the complement cascade at an early and essential point in the alternative complement pathway. |
| PC-73000 |
C5 complement inhibitor 7
C5 complement inhibitor
|
C5 complement inhibitor 7 (C5-IN-7) is a potent, small-molecule inhibitor of C5 complement protein with serum assay IC50 of <5 nM (2% human serum complement inhibition). |
| PC-72455 |
AMY-101
C3 inhibitor
|
AMY-101 (Cp40) is a peptidic inhibitor of the central complement component C3 for the management of patients with ARDS caused by SARS-CoV-2 infection. |
| PC-72006 |
C3aR antagonist JR14a
C3aR antagonist
|
C3aR antagonist JR14a is a potent and selective antagonist of human Complement C3a receptor (hC3aR) with IC50 of 10 nM (Inhibition of intracellular Ca2+ release induced by 100 nM C3a). |
| PC-72001 |
JPE1375
C5aR inhibitor
|
JPE1375 is a potent, peptidomimetic C5a receptor antagonist with IC50 of 39 nM, inhibits neutrophil influx in the RPAR in mice. |
